( Int J Obstet Anesth . 2023;56:103906. doi: 10.1016/j.ijoa.2023.103906) Neuraxial morphine is standard for postcesarean pain relief, yet morphine shortages lead to off-label use of alternative opioids. Buprenorphine, considered since the 1980s, lacks robust studies but shows promise. This study assesses buprenorphine's efficacy and side effects in current practice. After institutional approval, a retrospective analysis was conducted on women receiving neuraxial buprenorphine at a Tennessee community hospital from November 2019 to September 2020. All received intrathecal or epidural buprenorphine 0.3 mg. Exclusions included certain medical conditions.
No takes yet. Share an insight, caveat, or question.
Sorabella et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: